Giulia Cervetti

1.2k total citations
37 papers, 615 citations indexed

About

Giulia Cervetti is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Giulia Cervetti has authored 37 papers receiving a total of 615 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 20 papers in Pathology and Forensic Medicine and 12 papers in Oncology. Recurrent topics in Giulia Cervetti's work include Chronic Lymphocytic Leukemia Research (20 papers), Lymphoma Diagnosis and Treatment (20 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Giulia Cervetti is often cited by papers focused on Chronic Lymphocytic Leukemia Research (20 papers), Lymphoma Diagnosis and Treatment (20 papers) and CNS Lymphoma Diagnosis and Treatment (6 papers). Giulia Cervetti collaborates with scholars based in Italy. Giulia Cervetti's co-authors include Mario Petrini, Sara Galimberti, Nadia Cecconi, Rita Fazzi, F Caracciolo, Antonella Montanini, Massimo Federico, Nicola Di Renzo, Maura Brugiatelli and Stefano Luminari and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Giulia Cervetti

36 papers receiving 598 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Giulia Cervetti Italy 14 341 265 252 131 105 37 615
Annette Hänel Germany 8 462 1.4× 229 0.9× 307 1.2× 134 1.0× 89 0.8× 13 639
Sarah M. Larson United States 14 201 0.6× 200 0.8× 343 1.4× 262 2.0× 89 0.8× 74 749
Violaine Safar France 10 281 0.8× 171 0.6× 184 0.7× 96 0.7× 94 0.9× 24 529
A. M. Gianni Italy 15 201 0.6× 83 0.3× 294 1.2× 160 1.2× 101 1.0× 26 619
Craig A. Portell United States 16 409 1.2× 281 1.1× 322 1.3× 117 0.9× 50 0.5× 65 765
Deniz Şahin Türkiye 12 378 1.1× 164 0.6× 269 1.1× 57 0.4× 75 0.7× 52 594
Richard H. van der Jagt United States 10 740 2.2× 504 1.9× 484 1.9× 98 0.7× 102 1.0× 19 886
Gaetano Corazzelli Italy 14 493 1.4× 320 1.2× 215 0.9× 38 0.3× 82 0.8× 38 682
Parth Desai United States 12 295 0.9× 189 0.7× 289 1.1× 73 0.6× 53 0.5× 52 576
Takashi Akasaka Japan 15 323 0.9× 229 0.9× 194 0.8× 92 0.7× 37 0.4× 45 660

Countries citing papers authored by Giulia Cervetti

Since Specialization
Citations

This map shows the geographic impact of Giulia Cervetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giulia Cervetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giulia Cervetti more than expected).

Fields of papers citing papers by Giulia Cervetti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giulia Cervetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giulia Cervetti. The network helps show where Giulia Cervetti may publish in the future.

Co-authorship network of co-authors of Giulia Cervetti

This figure shows the co-authorship network connecting the top 25 collaborators of Giulia Cervetti. A scholar is included among the top collaborators of Giulia Cervetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giulia Cervetti. Giulia Cervetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Benedetti, E., Claudia Baratè, Emilia Bramanti, et al.. (2023). Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease. Journal of Clinical Medicine. 12(5). 1772–1772. 1 indexed citations
2.
Cencini, Emanuele, Ilaria Romano, Lara Mannelli, et al.. (2023). Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network). Annals of Hematology. 102(4). 841–849. 1 indexed citations
3.
Galimberti, Sara, Elena Ciabatti, Susanna Grassi, et al.. (2017). The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study. Frontiers in Pharmacology. 8. 413–413. 3 indexed citations
4.
Galeotti, Laura, F. Ceccherini, Marco Laurino, et al.. (2017). Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology. 79(4). 767–773. 7 indexed citations
5.
Guerrini, Francesca, Elena Ciabatti, Susanna Grassi, et al.. (2016). The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. Frontiers in Pharmacology. 7. 363–363. 29 indexed citations
6.
Paolo, Antonello Di, Giulia Cervetti, Claudia Baratè, et al.. (2014). The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. The Pharmacogenomics Journal. 14(4). 328–335. 36 indexed citations
7.
Cervetti, Giulia, et al.. (2013). Significant efficacy of 2-chlorodeoxyadenosine± rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up. Annals of Oncology. 24(9). 2434–2438. 16 indexed citations
8.
9.
Cervetti, Giulia, Sara Galimberti, Gabriele Buda, et al.. (2009). Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL).Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13.. Annals of Oncology. 21(4). 851–854. 3 indexed citations
10.
Cervetti, Giulia, et al.. (2009). Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Annals of Oncology. 21(4). 851–854. 28 indexed citations
11.
Galetta, Fabio, Ferdinando Franzoni, Giulia Cervetti, et al.. (2009). In vitro and in vivo study on the antioxidant activity of dexrazoxane. Biomedicine & Pharmacotherapy. 64(4). 259–263. 18 indexed citations
12.
Galimberti, Sara, Nadia Cecconi, Giulia Cervetti, et al.. (2007). EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL-LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCEDCHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica. 92. 24–24. 2 indexed citations
13.
Galetta, Fabio, Ferdinando Franzoni, Giulia Cervetti, et al.. (2005). Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomedicine & Pharmacotherapy. 59(10). 541–544. 36 indexed citations
14.
Galimberti, Sara, Giulia Cervetti, Nadia Cecconi, et al.. (2004). Quantitative Molecular Evaluation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia. Journal of Immunotherapy. 27(5). 389–393. 3 indexed citations
15.
Cervetti, Giulia, Sara Galimberti, Rita Fazzi, et al.. (2004). Rituximab as treatment for minimal residual disease in hairy cell leukaemia. European Journal Of Haematology. 73(6). 412–417. 40 indexed citations
16.
Cervetti, Giulia, Sara Galimberti, Nadia Cecconi, F Caracciolo, & Mario Petrini. (2004). Role of Low-Dose 2-CdA in Refractory or Resistant Lymphoplasmocytic Lymphoma. Journal of Chemotherapy. 16(4). 388–391. 4 indexed citations
17.
Cervetti, Giulia, F Caracciolo, Nadia Cecconi, Antonio Azzarà, & Mario Petrini. (2003). Efficacy and Toxicity of Liposomal Daunorubicin Included in PVABEC Regimen for Aggressive NHL of the Elderly. Leukemia & lymphoma. 44(3). 465–469. 4 indexed citations
18.
19.
Benedetti, E., Rita Fazzi, F Caracciolo, et al.. (2001). BK virus-associated cystitis in non-myeloablative and conventional transplant recipients with simultaneous cytomegalovirus reactivation successfully treated with cydofovir.. Haematologica. 10(86). 45–45. 7 indexed citations
20.
Petrini, Mario, Francesca Vaglini, Giulia Cervetti, et al.. (1999). Is lithium able to reverse neurological damage induced by vinca alkaloids?. Journal of Neural Transmission. 106(5-6). 569–575. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annette Hänel Breakdown of academic impact, for papers by Sarah M. Larson Breakdown of academic impact, for papers by Violaine Safar Breakdown of academic impact, for papers by A. M. Gianni Breakdown of academic impact, for papers by Craig A. Portell Breakdown of academic impact, for papers by Deniz Şahin Breakdown of academic impact, for papers by Richard H. van der Jagt Breakdown of academic impact, for papers by Gaetano Corazzelli Breakdown of academic impact, for papers by Parth Desai Breakdown of academic impact, for papers by Takashi Akasaka
Rankless by CCL
2026